바이오톡스텍

086040KOSDAQ자연과학 및 공학 연구개발업

59.8 / 100

Reference Date: 2026-07-24

Financial Score22.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 3.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioToxtek specializes in non-clinical CRO services, conducting toxicity and safety/efficacy evaluations using rodents and primates for pharmaceuticals, cell therapies, and chemicals. The company actively participates in new material development and is advancing the commercialization of therapeutic candidates like TB-4 and HX-1171 through technology licensing.

Number of Employees

241people

Average Salary

47.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

29.39Industry Average 43.646.5Point

Lower than industry avg (good)

PBR

1.09Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-4.74Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

44.42Industry Average 7.310.0Point

6.1x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲20.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
프롬바이오, 탈모 세포치료제 핵심 비임상 안전성 평가 착수
프롬바이오의 탈모 치료제 개발이 비임상 안전성 평가를 시작하며, 임상 진입 계획을 내년에 목표로 설정함으로써 바이오톡스텍 관련 분야의 긍정적 전망을 제공합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 2,175Won52-week high 3,92552-week low 1,983

1-month return4.0Point

1m +3.57% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral신주인수권부사채(해외신주인수권부사채포함)발행후만기전사채취득2026-07-08